HSD3B1: A Potential Drug Target for Hirsutism (G3283)

Target Name: HSD3B1

NCBI ID: G3283

HSD3B1

HSD3B1: A Potential Drug Target for Hirsutism

HSD3B1, also known as 3-beta-hydroxy-Delta(5)-steroid dehydrogenase, is a enzyme that plays a crucial role in the production of androgens, which are male sex hormones. In individuals with genetic conditions such as androgen insensitivity syndrome or hirsutism, high levels of androgens can cause a range of negative symptoms, including increased facial hair growth, acne, and prostate growth.

HSD3B1 is a member of the steroid dehydrogenase family, which includes enzymes that convert androgens to inactive compounds. In individuals with hirsutism, the primary cause of male pattern baldness, high levels of androgens can cause the hair to become thicker and more persistent, leading to an appearance of a halo or a \"messy\" head.

Research has shown that individuals with hirsutism are often male, have a low body mass index (BMI), and have a family history of androgen insensitivity syndrome. They may also have other conditions that increase their risk of developing hirsutism, such as obesity, diabetes, or a history of testicular cancer.

HSD3B1 is a potential drug target or biomarker for hirsutism, as it has been shown to be involved in the production of androgens and may play a role in the development of hirsutism. Studies have shown that individuals with hirsutism have lower levels of HSD3B1 than those without the condition. Additionally, inhibiting HSD3B1 has been shown to reduce androgens and improve the regression of hirsutism in individuals with the condition.

Furthermore, HSD3B1 has also been shown to be involved in the production of other androgens, such as androstenedione and androsterone. These compounds are produced by the 3-beta-hydroxy-Delta(5)-steroid dehydrogenase enzyme in the testes and play a role in the development and maintenance of male secondary sexual characteristics.

HSD3B1 is also an attractive target for drug development due to its relatively simple structure and the fact that it is primarily expressed in the testes. The drug development process for HSD3B1 inhibitors would likely involve the synthesis and testing of various compounds to identify those that have the potential to be effective in treating hirsutism.

In conclusion, HSD3B1 is a potential drug target or biomarker for hirsutism. Its involvement in the production of androgens and its potential to be inhibited make it a promising target for the development of new treatments for this debilitating condition. Further research is needed to fully understand the role of HSD3B1 in hirsutism and to identify effective inhibitors.

Protein Name: Hydroxy-delta-5-steroid Dehydrogenase, 3 Beta- And Steroid Delta-isomerase 1

Functions: A bifunctional enzyme responsible for the oxidation and isomerization of 3beta-hydroxy-Delta(5)-steroid precursors to 3-oxo-Delta(4)-steroids, an essential step in steroid hormone biosynthesis. Specifically catalyzes the conversion of pregnenolone to progesterone, 17alpha-hydroxypregnenolone to 17alpha-hydroxyprogesterone, dehydroepiandrosterone (DHEA) to 4-androstenedione, and androstenediol to testosterone. Additionally, catalyzes the interconversion between 3beta-hydroxy and 3-oxo-5alpha-androstane steroids controlling the bioavalability of the active forms. Specifically converts dihydrotestosterone to its inactive form 5alpha-androstanediol, that does not bind androgen receptor/AR. Also converts androstanedione, a precursor of testosterone and estrone, to epiandrosterone (PubMed:1401999, PubMed:2139411). Expected to use NAD(+) as preferred electron donor for the 3beta-hydroxy-steroid dehydrogenase activity and NADPH for the 3-ketosteroid reductase activity (Probable)

The "HSD3B1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HSD3B1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets